普華和順(01358.HK)2020年淨利同比增長670.7%至6.32億元
格隆匯 3 月 30日丨普華和順(01358.HK)公吿,截至2020年12月31日止年度全年業績,收入人民幣(下同)2.47億元,同比減少31.7%;公司擁有人應占溢利6.32億元,同比增長670.7%;基本每股盈利40.26分;董事建議派付每股普通股1.5766港元(2019年:無)的特別股息。
集團年內收入有所下降,主要由於2020年上半年若干地區的醫院就診人數減少,尤其是集團研發、製造及銷售高端輸液器以及靜脈留置針產品主要銷售區域,如北京、湖北省、黑龍江省等地的醫院人流大幅減少,日常就診需求下降,因此集團的收入顯著下降。
下半年居民出行逐漸復甦,醫療需求慢慢回升,集團下半年的業務經營收益下降幅度逐漸縮窄。相對而言,集團靜脈留置針業務的銷售區域受疫情影響相對有限,因此來自靜脈留置針業務的收入表現相對穩定。集團的靜脈留置針業務正處於成熟發展階段並在持續研發中,於未來仍有巨大的發展空間。
同時,靜脈留置針業務於2020年亦獲得了可觀的業務訂單,預期集團未來的靜脈留置針業務收益將呈現良好的發展趨勢。2020年,集團財政狀況及現金流量繼續保持穩定及健康。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.